Printer Friendly

SHERRY L. MESMAN APPOINTED AS CHIEF FINANCIAL OFFICER OF MOLECULAR BIOSYSTEMS

 SHERRY L. MESMAN APPOINTED AS CHIEF FINANCIAL OFFICER
 OF MOLECULAR BIOSYSTEMS
 SAN DIEGO, Aug. 3 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) announced today that Sherry L. Mesman has been appointed vice president, finance and chief financial officer, effective Aug. 1, 1992. In this position, Mesman will have full responsibility for the corporate finance, accounting, treasury and investor relations functions of the company.
 Most recently, Mesman, a CPA, has served as chief accounting officer and treasurer at MBI. Mesman joined the company in 1989 as director of accounting and MIS from the public accounting firm, Arthur Andersen & Co.
 Vincent A. Frank, MBI's president and chief operating officer, commented: "We are very pleased to announce the promotion of Sherry Mesman to vice president, finance and chief financial officer. She has been a valuable member of our senior management team. With her broad background in accounting and finance, we expect she will play a major role in the achievement of our strategic goals."
 Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound, magnetic resonance imaging and computerized tomography. Its flagship product, Albunex(R)-I.V., is currently awaiting final FDA approval.
 -0- 8/3/92
 /CONTACT: Beth Field Wallace of Molecular Biosystems, 619-452-0681 ext. 2212/
 (MB) CO: Molecular Biosystems Inc. ST: California IN: MTC SU: PER


JB-JL -- SD004 -- 6206 08/03/92 13:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1992
Words:237
Previous Article:BIO-RAD LABORATORIES ANNOUNCES SALE OF OPHTHALMIC DIVISION
Next Article:ALL ABOARD SUSQUEHANNA NO. 142! POPULAR STEAM TRAIN RIDES RETURN TO NORTHERN NEW JERSEY
Topics:


Related Articles
MOLECULAR BIOSYSTEMS INC. ANNOUNCES NEW HIRES AND PROMOTIONS
MOLECULAR BIOSYSTEMS RECEIVES ALLOWANCE ON U.S. PATENT FOR ORAL ULTRASOUND AGENT
MOLECULAR BIOSYSTEMS, DIRECTORS AND OFFICERS NAMED IN CLASS ACTION SUIT
MBI SUED BY COMPETITOR OVER ORAL AGENT
MBI ANNOUNCES ALBUNEX(R) APPROVAL IN JAPAN
MBI ANNOUNCES LAUNCH OF ALBUNEX(R) IN JAPAN
MBI DELIVERS UPDATE ON ALBUNEX
MOLECULAR BIOSYSTEMS ANNOUNCES SETTLEMENT OF SHAREHOLDER SUIT
MOLECULAR BIOSYSTEMS ANNOUNCES MANAGEMENT APPOINTMENTS
ALBUNEX(R) RECEIVES FDA APPROVAL; FIRST CONTRAST AGENT FOR ULTRASOUND

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters